GET DAILY SIGNALSProtara Therapeutics (TARA): Analyst $26 Target Points to +950% Upside Potential
Key Takeaways
- The central target of $26 is the arithmetic mean of seven verifiable analyst price targets, rounded from roughly $25.71, with a range of about $20 to $30.
- With TARA trading near $2.47, reaching $26 would require upside of roughly 950%—an unusually wide gap that largely reflects a steep share-price decline rather than a consensus forecast.
- Every analyst tracked maintains a Buy-equivalent rating, but targets have been trimmed in recent months, signaling caution even among bulls.
- The strongest support is clinical data for lead asset TARA-002 in bladder cancer and lymphatic malformations, plus a cash runway into 2028.
- The biggest risks are a deteriorating balance sheet, ongoing dilution, insider selling, and the wide distance between the stock price and the average analyst price target.
- For more detail on this ticker, explore its Major News and Today's Price Move, review the Forecast, and check Earnings before making any decision.
- You can also explore Trending AI Robots to see how AI-driven tools are monitoring stocks like this one.
Analyst Price Targets and Consensus View
Protara Therapeutics, Inc. (TARA) is a clinical-stage biopharmaceutical company developing therapies for cancer and rare diseases. Across seven individually verifiable analyst targets, the average price target is about $25.71, which I round to a central target of $26. The range runs from a low of $20 (LifeSci Capital, lowered from $22 in August 2026) to a high of $30 (TD Cowen). Other targets include H.C. Wainwright at $27, J.P. Morgan at $26 (trimmed from $27), JonesTrading at $25, Oppenheimer at $28 (raised from $25), and Piper Sandler at $24.
All published ratings are Buy-equivalent, but the direction of recent revisions is telling. Oppenheimer raised its target citing the opportunity in lymphatic malformations, while J.P. Morgan and LifeSci Capital lowered theirs. This divergence reflects uncertainty about timing and funding rather than disagreement about the science. Note that the gap between the price and these targets is unusually large because the shares have fallen more than 50% over the past year, and several targets have not yet been recalibrated to that move. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock last traded near $2.47, within a 52-week range of roughly $2.28 to $7.82. Reaching the $26 central target would require a gain of approximately 950%, which by any standard is a very large move. Such a repricing would likely require not just positive clinical readouts but a fundamental re-rating of the company's pipeline value, given a market capitalization of only about $146 million against analyst targets implying a valuation many times higher.
The path hinges on clinical milestones. TARA-002 has reported a 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and durable responses in a BCG-naïve cohort. The company intends to submit a Biologics License Application (BLA) for TARA-002 in lymphatic malformations in the second half of 2027.
What Could Support a Move Toward the Target
Positive data across two indications for TARA-002 is the central bull case. Strong response rates with a favorable safety profile support the view that the asset addresses meaningful unmet needs in bladder cancer and lymphatic malformations, where Breakthrough Therapy and Fast Track designations have been granted. The company also reports cash of roughly $142 million and a runway into 2028, reducing near-term liquidity risk. A second program, intravenous choline chloride for patients on parenteral nutrition, adds optionality. Several large institutional holders increased positions in recent quarters.
What Could Prevent the Target From Being Reached
The principal obstacle is financial: the company is unprofitable, with a trailing net loss near $70 million and no meaningful revenue, forcing reliance on equity financing. It has filed a $300 million shelf and a $100 million at-the-market program, which can dilute existing shareholders. Insider selling has increased, and short interest has risen. Clinical-stage biotechs also face binary event risk—any disappointing readout, regulatory delay, or financing shortfall could widen the gap to the target further. A continued drift in the shares would make even a downward revision of the average analyst price target look substantial relative to the market price.
Technical Levels and Market Structure
From a market-structure standpoint, the stock sits just above its 52-week low near $2.28, a level that has acted as support. The $2.50 area and the prior consolidation near $4.00–$4.20 represent potential resistance zones on any recovery, while the 52-week high of $7.82 is a far-distant technical reference. Because the shares are trading near multi-year lows, any move toward the $26 target would require sustained trend change rather than a simple breakout.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual horizons vary and are not always disclosed. For this stock, the more relevant catalysts are clinical and regulatory. Investors should watch interim data from the Phase 2 ADVANCED-2 trial, the Phase 2b dose-confirmation readout for IV choline chloride expected in the fourth quarter of 2026, updates on the planned BLA submission for lymphatic malformations, quarterly earnings and cash-burn commentary, financing activity, and any changes to analyst targets as the price and data evolve.
Final Assessment
The $26 central target is a rounded average of seven analyst price targets ranging from $20 to $30, but it sits roughly 950% above the current price of about $2.47. The bull case rests on compelling clinical data for TARA-002 and a cash runway into 2028, while the bear case centers on persistent losses, ongoing dilution, insider selling, and the risk that targets have simply not caught down to a lower share price. The distance to the target is very large, and reaching it would require both clinical success and a major re-rating. Investors should monitor data readouts, the BLA timeline, and financing developments, and should not treat the average analyst price target as a guarantee of future performance.
AI Daily Buy/Sell Signals
In my research process I often turn to Tickeron’s AI Daily Buy/Sell Signals for an additional layer of monitoring on names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market shifts. For a clinical-stage name with event-driven volatility, it helps surface potential opportunities and track trend changes more efficiently alongside my own analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TARA's RSI Indicator recovers from oversold territory
The RSI Indicator for TARA moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for TARA just turned positive on October 21, 2026. Looking at past instances where TARA's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Following a +10.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where TARA advanced for three days, in 174 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TARA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TARA as a result. In 79 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for TARA entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.905) is normal, around the industry mean (3.037). P/E Ratio (-1.816) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. TARA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage company, which engages in developing treatments for rare and specialty diseases with significant unmet needs.
Industry Biotechnology
Advertisement